BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22170262)

  • 1. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
    Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG
    Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
    Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
    J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
    McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
    PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
    Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
    Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
    Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
    Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
    Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
    Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
    Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
    Barwick T; Bencherif B; Mountz JM; Avril N
    Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
    Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.